In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".

Example Input: Paragraph: Feline coronavirus (FCoV) is common among cats living indoors in groups. In about 10% of infected cats, a potentially lethal disease, feline infectious peritonitis (FIP) occurs. Virus transmission is faecal-oral. Mutian® Xraphconn (Mutian X) is a product marketed to treat cats with FIP but is also being used to stop virus shedding, although no clear guidelines exist for its use for this purpose. The aim of this study was to establish the minimum dose and treatment duration required to ensure viral clearance from the faeces of asymptomatic virus-shedding cats. In five multicat households, 29 cats naturally infected with FCoV and actively shedding virus in the faeces were given Mutian X pills. Virus shedding was monitored using reverse-transcription quantitative polymerase chain reaction (RT-qPCR) controlled for faecal inhibitors to ensure sensitivity. Mutian X given orally cleared the virus in 29 cats; although four cats required a repeated course to finally stop virus shedding. A dose of 4 mg/kg q24 h for four days was found to be the optimal treatment protocol: 2 mg/kg cleared only 80% of cats. Posttreatment using a sensitive RT-qPCR test was essential to ensure that virus clearance had been achieved, since failure to clear even one cat can result in re-infection of the others. Records of virus shedding by cats before treatment provided a retrospective control: significantly more cats stopped shedding virus after Mutian X than recovered from infection during the control period (p < .00001). This is the first report of the successful elimination of faecal FCoV shedding in chronically infected cats. 
 Title: Oral Mutian®X stopped faecal feline coronavirus shedding by naturally infected cats
Example Output: True

Example Input: Paragraph: The pathology of 2 zoonotic human viral infections that recently emerged, severe acute respiratory syndrome (SARS) due to coronavirus (SARS-CoV) and avian influenza A subtype H5N1, is reviewed and compared based on the literature and the cases examined by the authors. Pneumocytes are the primary target of infection resulting in diffuse alveolar damage. Systemic cytokine activation results in hemophagocytic syndrome, lymphoid depletion, and skeletal muscle fiber necrosis. Severe acute respiratory syndrome induces a more fibrocellular intra-alveolar organization with a bbronchiolitis obliterans organizing pneumoniaQ-like pattern and presence of multinucleated histiocytes and pneumocytes. H5N1 causes a more fulminant and necrotizing diffuse alveolar damage with patchy and interstitial paucicellular fibrosis. Severe acute respiratory syndrome associated coronavirus persists in the lung up to the second month, whereas H5N1 persists in the lung up to the third week. Severe acute respiratory syndrome associated coronavirus disseminates to blood, urine, feces, gastrointestinal tract, and liver. There is recent report of possible cerebral involvement by H5N1 and its isolation in the blood, gastrointestinal tract, and cerebrospinal fluid. More pathologic studies are urgently needed. D 
 Title: The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1-a review
Example Output: True

Example Input: Paragraph: The original scientifi c strategy behind vaccinology has historically been to "isolate, inactivate, and inject," fi rst invoked by Louis Pasteur. The recombinant DNA and nanotechnology did much enlarge the repertoire on vaccines, which is today based on three adjusted principles, attenuation, inactivation, and recombination, as shown in Fig. 9 .1 . The three principles are regarded as equal, and all experimental possibilities for a new vaccine development against a pathogen should be studied in detail. The recombinant DNA and nanotechnology did not change the basic scientifi c strategy: live and non-live vaccines. Live vaccines are non-adjuvanted, and non-live vaccines are generally adjuvanted. New developments against tuberculosis (TB) highlight this broad experimental approach: Today, it estimated that about one-third of the world population is infected with the TB bacillus. Approximately 54 million people are infected every year, 9.4 million develop the disease, and 1.7 million die from this curable disease. The TB bacillus kills more people than any other infectious agent alone. Currently, BCG (Bacillus Calmette-Guérin) is the only vaccine recommended by the WHO, with more than three billion doses administered since its introduction in 1921. BCG is prepared from a strain of the attenuated live bovine tuberculosis bacillus, Mycobacterium bovis , which lost its virulence in humans by being specially subcultured in an artifi cial medium. However, although it protects newborns and children from severe forms of TB, its effi cacy against pulmonary TB in adolescents and adults is far from optimal, with protection rates varying between 0 and 80 % according to the geographical area. Contents Live and Non-live Vaccines 
 Title: Types of Recombinant Vaccines 9.1 Live and Non-live Vaccines
Example Output:
True